Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...

Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Sarepta Therapeutics Inc said the U.S. drug regulator could initially approve its gene therapy for a muscle wasting disorder for a smaller patient group after the agency deferred an accelerated ...

Sarepta Forward Looking Statement This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed ...

Sarepta’s stock jumped more than 30% on Friday following news that the Food and Drug Administration expanded the pool of patients eligible for its Duchenne muscular dystrophy (DMD) drug, Elevidys.